

# Contents

*Preface*

*Contributors*

## **Chapter 1 Introduction 1**

B.W.K. Diehl

|       |                 |   |
|-------|-----------------|---|
| 1.1   | The Instrument  | 2 |
| 1.2   | Principles      | 2 |
| 1.2.1 | Spectra         | 2 |
| 1.2.2 | Response        | 3 |
| 1.2.3 | Reproducibility | 3 |
| 1.2.4 | Calibration     | 3 |
| 1.3   | Experimental    | 4 |

## **Chapter 2 NMR Spectroscopy in the European Regulatory Dossier 5**

S. Branch

|       |                                           |    |
|-------|-------------------------------------------|----|
| 2.1   | Directives, Rules and Guidelines          | 5  |
| 2.2   | Information Required to Establish Quality | 6  |
| 2.3   | Control of Starting Materials             | 8  |
| 2.3.1 | Specifications and Routine Tests          | 8  |
| 2.3.2 | Scientific Data                           | 10 |
| 2.4   | Control of the Finished Product           | 13 |
| 2.5   | Stability Studies                         | 14 |
| 2.6   | Concluding Remarks                        | 15 |

## **Chapter 3 Analysis of Drugs 16**

B.W.K. Diehl and U. Holzgrabe

|       |                                                                           |    |
|-------|---------------------------------------------------------------------------|----|
| 3.1   | NMR Spectroscopy in International Pharmacopoeias and Related Applications | 16 |
| 3.1.1 | Polymers                                                                  | 22 |
| 3.1.2 | Biomolecules                                                              | 26 |
| 3.2   | Identification and Quantification of Impurities in Drugs                  | 32 |
| 3.2.1 | Impurities Resulting from the Synthesis Pathway                           | 32 |
| 3.2.2 | Decomposition Reactions                                                   | 36 |
| 3.3   | Quantification of Drugs in Dosage Forms                                   | 43 |
| 3.3.1 | Analysis of Single Drugs in Dosage Forms                                  | 43 |



|     |                       |     |
|-----|-----------------------|-----|
| 7.5 | Capillary Separations | 113 |
|-----|-----------------------|-----|

## **Chapter 8 NMR of Body Fluids 118**

U. Holzgrabe

|       |                                                             |     |
|-------|-------------------------------------------------------------|-----|
| 8.1   | NMR of Urine - Studies of Metabolism                        | 118 |
| 8.1.1 | <sup>1</sup> H NMR Spectroscopy                             | 118 |
| 8.1.2 | <sup>19</sup> F NMR Spectroscopy.                           | 122 |
| 8.1.3 | <sup>15</sup> N NMR Spectroscopy                            | 124 |
| 8.1.4 | <sup>31</sup> P NMR Spectroscopy                            | 124 |
| 8.2   | NMR of Bile, Blood Plasma, Cerebrospinal and Seminal Fluids | 125 |
| 8.3   | LC NMR Hyphenation                                          | 128 |

## **Chapter 9 NMR as a Tool in Drug Research 134**

G. Gemmecker

|        |                                         |     |
|--------|-----------------------------------------|-----|
| 9.1    | Introduction                            | 134 |
| 9.2    | Protein Structures from NMR             | 135 |
| 9.3    | Protein-Ligand Interactions             | 136 |
| 9.3.1  | NMR of Molecular Complexes              | 136 |
| 9.3.2  | Aspects of Binding Affinity             | 137 |
| 9.3.3  | Exchange Time Scales for NMR Parameters | 139 |
| 9.3.4  | Transfer NOE                            | 140 |
| 9.3.5  | Isotope Filters                         | 142 |
| 9.3.6  | Measuring Binding Affinities by NMR     | 144 |
| 9.3.7  | Binding Site Localization               | 147 |
| 9.3.8  | Solvent-Accessible Surfaces             | 149 |
| 9.3.9  | Screening Protein-Ligand Interactions   | 149 |
| 9.3.10 | Conclusion                              | 151 |

## **Chapter 10 Ligand-Cyclodextrin complexes 154**

B. Chankvetadze, G. Blaschke and G. Pintore

|        |                                                                    |     |
|--------|--------------------------------------------------------------------|-----|
| 10.1   | Introduction                                                       | 154 |
| 10.2   | Cyclodextrins and their Properties                                 | 155 |
| 10.3   | Application of Cyclodextrins in Drug Development and Drug Analysis | 157 |
| 10.4   | NMR Spectroscopic Studies of Ligand-CD Complexes                   | 159 |
| 10.4.1 | Stoichiometry of Ligand-CD Complexes                               | 159 |
| 10.4.2 | Binding Constants of Ligand-CD Complexes                           | 164 |
| 10.4.3 | Structure and Dynamics of Ligand-CD Complexes                      | 166 |

## **Chapter 11 Ligand-Membrane Interaction** **174**

J.K. Seydel

|          |                                                                                                                                |     |
|----------|--------------------------------------------------------------------------------------------------------------------------------|-----|
| 11.1     | Introduction                                                                                                                   | 174 |
| 11.2     | Functioning, Composition and Organization of Membranes                                                                         | 174 |
| 11.2.1   | The Physiology of Cells and the Importance of Membranes for their Functioning                                                  | 174 |
| 11.2.2   | Composition and Organization of Membranes                                                                                      | 175 |
| 11.2.2.1 | Mammal Membranes                                                                                                               | 175 |
| 11.2.2.2 | Artificial Membranes and Liposome Preparation                                                                                  | 183 |
| 11.2.3   | Dynamic Molecular Organisation of Membranes                                                                                    | 184 |
| 11.2.3.1 | Thermotropic and Lysotropic Mesomorphism of Phospholipids                                                                      | 185 |
| 11.2.3.2 | Phase separation and domain formation                                                                                          | 186 |
| 11.2.4   | Possible Effects of Drugs on Membranes and Effects of Membranes on Drugs                                                       | 187 |
| 11.3     | NMR Spectrometry; an Analytical Tool for the Study and Quantification of Ligand-Membrane Interactions                          | 190 |
| 11.3.1   | Tools for the Analysis and Quantification of Drug-Membrane Interactions                                                        | 190 |
| 11.3.2   | Study of Membrane Polymorphism by $^{31}\text{P}$ -NMR                                                                         | 192 |
| 11.3.3   | Effect of Cholesterol and Diacylglycerols                                                                                      | 194 |
| 11.3.4   | Effect of Drugs                                                                                                                | 195 |
| 11.3.4.1 | $^{31}\text{P}$ -NMR to Study Changes in Orientation of Phospholipid Head Groups.                                              | 196 |
| 11.3.4.2 | $^{31}\text{P}$ -NMR to Study Drug Transmembrane Transport                                                                     | 199 |
| 11.3.4.3 | $^1\text{H}$ -NMR in Combination with $\text{Pr}^{3+}$ for the Studying of Drug-Location                                       | 203 |
| 11.3.4.4 | The Use of $^2\text{H}$ -NMR and $^{13}\text{C}$ -NMR to Determine the Degree of Order and the Molecular Dynamics of Membranes | 206 |
| 11.3.4.5 | Change in Relaxation Rate $1/T_2$ ; a Method of Quantifying Drug-Membrane Interaction                                          | 208 |
| 11.3.4.6 | NOE-NMR in the Study of Membrane Induced Changes in Drug Conformation                                                          | 217 |
| 11.3.4.7 | Combination of Methods and Techniques for the Studying of Drug-Membrane Interactions                                           | 220 |
| 11.4     | Concluding remarks                                                                                                             | 226 |

## **Chapter 12 Solid-State NMR in Drug Analysis** **231**

I. Wawer

|      |                                                                      |     |
|------|----------------------------------------------------------------------|-----|
| 12.1 | Fundamentals and Techniques of Solid State NMR                       | 231 |
| 12.2 | Solid State Conformations of Drugs and Biologically Active Molecules | 241 |
| 12.3 | Polymorphism/Pseudopolymorphism of Drugs                             | 245 |
| 12.4 | Studies of Tablets and Excipients                                    | 252 |

## **Chapter 13 MR Imaging and MR Spectroscopy 257**

I. Wawer

|        |                                                  |     |
|--------|--------------------------------------------------|-----|
| 13.1   | In vitro and in vivo Measurement Methods         | 257 |
| 13.2   | $^1\text{H}$ MR Imaging of Tablets               | 261 |
| 13.3   | $^1\text{H}$ Imaging of Plants                   | 265 |
| 13.4   | Studies on Biopsy Samples and Tissues            | 269 |
| 13.5   | Multinuclear Preclinical Measurements in Animals | 273 |
| 13.6   | MRI and MRS in Humans                            | 277 |
| 13.6.1 | Studies of brain.                                | 277 |
| 13.6.2 | MR Imaging of Breast                             | 283 |
| 13.6.3 | Musculoskeletal Tumors                           | 284 |
| 13.6.4 | Other Studies                                    | 286 |

## **Concluding remarks 294**

U. Holzgrabe

